威斯达研究所与OncoCyte公司扩大肺癌检测技术协议

  近日，美国宾夕法尼亚大学威斯达研究所（Wistar Institute）和OncoCyte公司表示，他们合作扩大了一项之前的协议，旨在开发肺癌早期检测的诊断测试技术。
  在2013年底，两家公司就发起了一项合作协议开发新型的检测技术来鉴别潜在的基于基因表达为基础的肺癌生物标志物；在近日的扩大协议的帮助下，两家公司或将开发出高敏感性及特异性的非侵入性血液检测技术，用于对早期肺癌进行检测。
  合作的下一个阶段两家公司将会对病人研究组进行扩大研究，并且将样本分析转移到平台中操作以帮助进行商业化的操作；未来Wistar和OncoCyte的研究者将会正式mRNA和miRNA的表达，并且完成诊断测试的炎症，研究者或将在2016年完成最后的证实工作。
  OncoCyte是BioTime的子公司，其可以获得独家的许可证进行发病、发现及技术的研发工作，未来OncoCyt期望同同Wistar完成明确的许可协议。两家公司研究协议的扩展将跟随积极的临床试验结果而开展，而在美国胸科学会国际会议上研究者就阐明了一种基于生物标志物的高敏感性及特异性的血液检测技术，通过进行预实验，新检测技术的敏感性达到了76%，特异性达到了88%。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Wistar Institute, OncoCyte Expand Lung Cancer Dx Collaboration

The Wistar Institute and OncoCyte said today they are expanding a prior agreement aimed at developing a diagnostic test for the early detection of lung cancer. 

In late 2013, the partners inked a sponsored research agreement to develop and test potential gene expression-based lung cancer biomarkers identified by Louise Showe, a professor in Wistar's Molecular and Cellular Oncogenesis program. Under the expanded deal, Wistar and OncoCyte will develop a highly sensitive and specific non-invasive, blood-based test. 

In the next phase of the development, the partners will analyze an expanded patient set, and transfer the sample analysis to a platform that can be operated at commercial scale. Further, Wistar and OncoCyte researchers will confirm mRNA and miRNA expression, and complete diagnostic test verification, with the aim of completing final validation of the test in 2016, followed by a commercial launch. 

OncoCyte, a subsidiary of BioTime, has exercised options to obtain exclusive licenses to inventions, discoveries, or technologies resulting from the collaboration. It expects to finalize definitive licensing agreements with Wistar in the future. 

The expansion of the collaboration follows positive clinical interim results that were presented at the American Thoracic Society International Conference in the spring that demonstrated a high level of sensitivity and specificity for the blood-based test developed based on the biomarkers identified by Showe. According to the preliminary results, the test had an area under the curve of .88 with sensitivity of 76 percent and specificity of 88 percent.